BUZZ-Jefferies trims CSL's PT but stays upbeat on growth; shares rise
Reuters
Oct 02
BUZZ-Jefferies trims CSL's PT but stays upbeat on growth; shares rise
** Jefferies lowers CSL's CSL.AX PT to A$275 from A$288, but remains constructive on long-term growth, highlighting continued plasma products market underpenetration and rational industry dynamics
** Brokerage expects the biotech major to deliver high single-digit EPS growth over the medium term
** Says stock is trading at 17.6x forward P/E, nearly half its historic level, which it sees as “too cheap”
** Shares advance as much as 3.2% to A$205.080, though are down 27.2% YTD, including today's gains
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.